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The Rationale for Adjuvant Chemotherapy in Stage I
Non-small Cell Lung Cancer
Leora Horn, MD, MSc, FRCPC,* Alan B. Sandler, MD,† Joe B. Putnam, Jr., MD, FACS,‡
and David H. Johnson, MD, FACP†
Abstract: The past decade has witnessed renewed interest in studies
exploring the benefits of adjuvant (postoperative) chemotherapy
( radiation therapy) in patients with resected non-small cell lung
cancer (NSCLC). Recently completed adjuvant trials have included
a heterogeneous group of patients with resected stages I to IIIA
NSCLC. With rare exception, the published results of these studies
indicate adjuvant chemotherapy imparts a significant overall sur-
vival advantage. Subset analyses suggest survival benefit occurs
primarily in patients with resected stage II or IIIA and is less likely
to occur in stage I patients. This apparent lack of survival benefit in
stage I patients was seemingly validated in a prospective trial
conducted by the Cancer and Leukemia Group B in which stage IB
patients were randomized to observation or adjuvant carboplatin and
paclitaxel. Survival at 5 -years was identical in the two arms of this
trial. By contrast, two contemporary postoperative chemotherapy
trials also conducted exclusively in stage I NSCLC patients yielded
positive survival results. The divergent outcome of the prospective
trials along with the negative subset analyses has created uncertainty
as to the utility of postoperative adjuvant chemotherapy in stage I
NSCLC. Herein we review the data underlying this controversy and
offer a proposed algorithm to aid the clinician in selecting patients
whom we believe may benefit from adjuvant chemotherapy. The
treatment algorithm is based on currently available tumor- and
host-related factors that affect prognosis.
Key Words: Non-small cell lung cancer, Adjuvant chemotherapy,
Stage I non-small cell lung cancer.
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There is no such uncertainty as a sure thing.—Robert Burns
The role of postoperative adjuvant cisplatin-based chemo-therapy in good performance status patients with com-
pletely resected stage II and IIIA non-small cell lung cancer
(NSCLC) is now firmly established.1–3 Less clear and some-
what controversial, however, is the role of adjuvant chemo-
therapy in patients with resected stage I NSCLC.2–4 The
controversy stems in part from subgroup analyses of recently
completed adjuvant trials data that suggest that stage I pa-
tients do not obtain a meaningful survival improvement after
postoperative chemotherapy.5,6 This is perhaps somewhat
surprising because extrathoracic metastases are the most
common site of recurrence in resected stage I patients,7 and
one would predict a favorable effect with systemic therapy.
Nonetheless, the verisimilitude of the subgroup analyses has
been bolstered by the negative results of a Cancer and
Leukemia Group B (CALGB) phase III trial that specifically
addressed the utility of adjuvant chemotherapy in stage IB
NSCLC.8,9 Although the initial report of the CALGB study
indicated postoperative carboplatin and paclitaxel imparted a
significant survival advantage compared with no adjuvant
therapy,8 the survival benefit was no longer apparent on
longer follow-up.9 The purpose of this review is to briefly
address the data underlying the current controversy and to
provide recommendations to the practicing oncologist vis-a`-
vis the advisability of adjuvant chemotherapy in selected
stage I NSCLC patients.
ADJUVANT CHEMOTHERAPY IN NSCLC
An evaluation of adjuvant studies completed prior to
December 31, 1991 was included in a landmark 1995 meta-
analysis of 52 randomized chemotherapy trials in NSCLC.10
Globally, no improvement in overall survival was identified
after postoperative chemotherapy. However, when analyzed
by composition of the adjuvant chemotherapy regimen, there
was a nonsignificant 13% reduction in the risk of death
observed with platinum-based regimens, which translated
into an absolute survival benefit of 5% at 5 years (p 
0.08).10 The magnitude of the cisplatin-related survival ben-
efit was similar to that observed with adjuvant chemotherapy
in early-stage breast cancer,11 prompting several groups to
initiate a new series of adjuvant trials in NSCLC. The
post-1995 adjuvant studies generally employed newer gener-
ations of platinum-based chemotherapy regimens.5,6,9,12–15
Some of the trials also permitted the use of postoperative
radiotherapy. Collectively, the results of these trials clearly
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support the use of postoperative therapy in good performance
status patients with stage II or IIIA NSCLC (Table 1).1–3
Meta-analyses of these data estimate a relative risk reduction
in mortality of 11% to 13% at 5 years.16–18
THE STAGE I ADJUVANT CHEMOTHERAPY
CONTROVERSY
Three of the post-1995 meta-analysis adjuvant trials
specifically addressed the issue of postoperative chemother-
apy in resected stage I NSCLC.9,14,19 A fourth study was
limited to patients with stage IB and II disease,5 whereas the
remaining studies all enrolled patients with stage I to III
disease6,12,13,15 (Table 2). Subset analyses were performed in
the latter trials based on stratification factors. The controversy
surrounding the use of adjuvant chemotherapy in stage I
NSCLC stems from the seemingly contradictory results of the
stage I trials and subset analyses of the larger studies.
The largest of the stage I adjuvant trials randomized
999 patients with adenocarcinoma of the lung to observation
or 2 years of treatment with uracil-tegafur.14 At the time of
publication, median survival had not been reached in either
group. Five-year survival favored the uracil-tegafur–treated
group (88% versus 85%; hazard ratio [HR]  0.71; p 
0.04). In a subgroup analysis, patients with T1 lesions (i.e.,
stage IA disease) had 5-year survival rates that were virtually
indistinguishable between the treated and control groups
(89% versus 90%; p  0.87). By contrast, the 5-year survival
rate among uracil-tegafur–treated patients with T2 lesions
(i.e., stage IB disease) was significantly higher than those in
the control group (85% versus 74%; p  0.005).
CALGB Study 9633 limited enrollment to patients with
T2N0M0 lesions (i.e., stage IB NSCLC) and randomized
subjects to observation or four cycles of carboplatin plus
paclitaxel.9 Although the original study design called for an
accrual of 500 patients, the enrollment target was reduced to
TABLE 1. Results of Recent Postoperative Adjuvant Trials in NSCLC
Trial Stage Treatment Pt. No. 5-yr Survival Rate, % HR p
ALPI12 I–III Surgery 540 45 0.96 0.59
MVP 548 50
IALT13 I–III Surgery 935 40.4 0.86 0.03
CDDP-based 932 44.5
ANITA6 IB–IIIA Surgery 433 42.6 0.80 0.017
CDDP  VNB 407 51.2
BLT15 I–IIIA Surgery 189 58a 1.02 0.90
CDDP-based 192 60a
NCI-C5 IB–II Surgery 240 54 0.60 0.03
CDDP  VNB 242 69
CALGB9 IB Surgery 171 57 0.80 0.10
CBDCA  Pac 173 59
JLCRG14 IA–Bb Surgery 488 85 0.71 0.047
UFT 491 88
Rosselli et al.19 IB Surgery 70 42 NR 0.02
CDDP  E 70 62
NSCLC, non-small cell lung cancer; Pt., patient; HR, hazard ratio; ALPI, Adjuvant Lung Cancer Project Italy; MVP, mitomycin, vinblastine,
and cisplatin; IALT, International Adjuvant Lung Cancer Trial; CDDPVNB, cisplatin  vinorelbine; BLT, Big Lung Trial; ANITA, Adjuvant
Navelbine International Trialist Association; NCI-C, National Cancer Institute of Canada; CALGB, Cancer and Leukemia Group B; JLCRG, Japan
Lung Cancer Research Group; CBDCA  Pac, carboplatin  paclitaxel; UFT, uracil-tegafur; CDDP  E, cisplatin  etoposide.
a Two-year survival.
b Adenocarcinomas only.
TABLE 2. Hazard Ratios by Stage in Recent Postoperative
Adjuvant Trials in NSCLC
Trial Stage HR 95% CI
ALPI12 I 0.97 0.71–1.33
II 0.80 0.60–1.06
IIIA 1.06 0.82–1.38
IALT13 I 0.97a NR
II 0.93a NR
III 0.81a NR
ANITA6 IB 1.10 0.76–1.57
II 0.71 0.49–1.03
IIIA 0.69 0.53–0.90
BLT15 I 0.99b NR
II 1.25b NR
III 0.70b NR
NCI-C5 IB 0.94 NR
II 0.59 0.42–0.85
CALGB9 IB 0.80 0.60–1.07
JLCRG14 IA 0.97 0.64–1.46
IB 0.48 0.29–0.81
NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval;
ALPI, Adjuvant Lung Cancer Project Italy; IALT, International Adjuvant Lung Cancer
Trial; ANITA, Adjuvant Navelbine International Trialist Association; BLT, Big Lung
Trial; NCI-C, National Cancer Institute of Canada; CALGB, Cancer and Leukemia
Group B; JLCRG, Japanese Lung Cancer Research Group; NR, not reported.
a Estimate only, taken from 2004 American Society of Clinical Oncology presentation.
b Estimates taken from Waller et al.15
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384 patients as an alternative to study termination due to slow
accrual.8 In addition, the trial was originally designed for
two-sided hypothesis testing but was converted to one-sided
testing (one-sided  of 0.05 and an 80% power to detect an
HR of 0.67) when the sample size was reduced “to maintain
feasibility and statistical power.”8 A planned interim analysis
demonstrated a “P value for overall survival that was less
than a prespecified stopping boundary,” prompting study
closure by the Data Monitoring and Safety Committee. The
trial enrolled 344 patients, of whom 330 were eligible and
received the intended therapy. Among patients treated with
carboplatin and paclitaxel, the 4-year survival was 71%
compared with 59% for the control arm (HR  0.62; 95%
confidence interval [CI]: 0.41–0.95; p  0.028).8 Two years
later, an update of the study revealed no statistical difference
in the 5-year survival rates (59% versus 57%) (HR  0.80;
95% CI: 0.60–1.07; p  0.10).9 Disease-free survival, how-
ever, remained statistically significantly superior with adju-
vant treatment.
Roselli et al.19 conducted an adjuvant study that was
similar in design to the CALGB trial, albeit much smaller.
These investigators randomized 140 stage IB patients to six
cycles of cisplatin plus etoposide or observation. In contrast
to the CALGB results, 5-year survival favored the platinum
treatment group (62% versus 42%; p  0.02). The extremely
poor survival observed in the control arm of this trial relative
to the control arms of contemporary trials involving IB
patients is noteworthy and may be related to patient selection
factors, the quality of the surgery, or possibly both.
A North American Intergroup trial led by the National
Cancer Institute of Canada (BR.10) randomized 482 patients
with stage IB or II NSCLC to observation or four courses of
cisplatin plus vinorelbine.5 Approximately 45% of patients
had stage IB disease. Median survival was significantly
prolonged in the chemotherapy group (94 versus 73 months;
p  0.04). At 5 years, there was an absolute survival advan-
tage of 15% in favor of adjuvant chemotherapy (69% versus
54%). Subgroup analyses according to stratification factors,
however, failed to show a statistically significant improve-
ment in survival among treated patients with stage IB disease
(although there was an absolute 7% increase in 5-year sur-
vival with chemotherapy). In contrast, there was a 20%
improvement in 5-year survival among treated stage II pa-
tients compared with the observation group, a highly statis-
tically significant difference (p  0.004).
The Adjuvant Navelbine International Trialist Associ-
ation study also employed cisplatin and vinorelbine adjuvant
chemotherapy and enrolled 840 patients with stage IB to IIIA
disease.6 Thirty-six percent of the patients had stage IB
disease. With a median follow-up of more than 6 years,
median survival was significantly superior in the chemother-
apy-treated group (65.7 versus 43.7 months; p  0.017).
Five-year survival favored the chemotherapy group (51.2%
versus 42.6%). In a subset analysis, however, there was no
difference in 5-year survival rates among stage IB patients
with or without adjuvant treatment (62% versus 64%).6 Cor-
responding values for stage II disease were 52% and 39%
for treatment and observation, respectively (results that
more or less mirror the BR.10 subset analysis) and 42%
and 26% for those with stage IIIA disease. However,
because the test of interaction between tumor stage and
chemotherapy on survival was not significant, a definitive
conclusion is not possible.6
Five of the cisplatin-based adjuvant chemotherapy tri-
als listed in Table 1 were included in a recently completed
meta-analysis,5,6,12,13,15 the so-called Lung Adjuvant Cispla-
tin Evaluation analysis.17 Despite the increased statistical
power, there was not a survival benefit among stage I pa-
tients. In fact, if anything, there was a trend toward detriment
with treatment in patients with stage IA disease. The effect of
adjuvant chemotherapy in stage IB disease appeared to be
neutral. None of the stage I–only adjuvant trials were in-
cluded in this analysis.
THE STAGE I NSCLC CONTROVERSY
The data outlined above appear contradictory. How-
ever, in our view, the contradictions may be explained in part
by the nature of subset analyses and the heterogeneity of
stage I NSCLC. First, subset analyses have only power to
detect substantially larger effects on the endpoint of interest,
not a smaller effect.20–22 The overall trial result is usually a
better guide to the direction of effect in subgroups than the
apparent effect observed within a subgroup.23 Accordingly,
the subset analyses outlined above should be viewed cau-
tiously. Second, stage I NSCLC is not a single, homogeneous
disease. The heterogeneity is recognized to a degree in the
extant staging system by the creation of the subcategories IA
and IB, based in part on tumor size. Tumors larger than 3 cm
are classified as T2 and those 3 cm or smaller are deemed
T1.24 Although patients with T1 lesions tend to have a better
survival compared with those with T2 lesions, there is noth-
ing biologically unique about 3.0 cm. Tumors do not sud-
denly become more aggressive at 3.01 cm or less aggressive
at 2.99 cm. Rather, prognosis worsens incrementally with
increasing tumor size (Figure 1).25–27 One could just as easily
use 5.0 cm as a convenient, clinically relevant dividing point
FIGURE 1. Reconstructed survival curves in stage I non-
small cell lung cancer by tumor size.
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between IA and IB disease as lesions of this size and larger
have a prognosis similar to that for T3 tumors.26 Once a
primary lung tumor exceeds 7.0 cm in diameter, overall
prognosis closely approximates that for a patient with stage
IIB disease and is only marginally better than that for an
individual with stage IIIA disease.26,28 The current dividing
point between T1 and T2 lesions is clinically relevant none-
theless. A node-negative lesion larger than 3 cm (i.e.,
T2N0M0 or stage IB) is a particularly bad disease with a
5-year rate survival of approximately 50% to 55%, which is
more or less equivalent to that of a T1N1M0 lesion or stage
IIA disease (Figure 2),29 and far worse than the 75% to 80%
5-year survival rate observed in stage IA disease.29 T2 lesions
are also defined by the presence of visceral pleural involve-
ment (VPI), atelectasis or lobar obstruction extending to the
hilar region, or a lesion located at least 2 cm distal to the
carina.24 In most surgical series, T2 lesions are characterized
by tumor size or VPI, which is found in up to 30% of stage
IB lesions.30 VPI turns out to be a much underrated poor
prognostic factor as lesions with VPI have 5-year survival
rates lower than 50%, independent of tumor size.30–33
STAGE I NSCLC AND ADJUVANT
CHEMOTHERAPY
Given the conflicting data, what should the practicing
oncologist do when confronted with a patient with a resected
stage I NSCLC? One option would be to present the available
data and simply let the patient choose a course of action.
However, this approach is viewed by some ethicists as an
abrogation of one’s professional obligations and may be
unacceptable to the patient.34 To help guide one’s decision
making, we developed the algorithm shown in Figure 3. The
algorithm is based on a combination of easily obtained tumor-
and host-related factors including lesion size, the presence or
absence of VPI, the extent of lymph node sampling, patient
performance status, and the presence or absence of comor-
bidities.
As noted above, there is no specific tumor size that
conveniently segregates tumors into those with “good” or
“poor” survival. Interestingly, in the upcoming U.S. inter-
group adjuvant trial, investigators will use a T diameter 4 cm
or larger to select stage IB patients for inclusion based on a
subset analysis of the CALGB 9633 data suggesting chemo-
therapy imparted a survival benefit in patients with tumors 4
cm or larger.35 Although one could make a strong argument
for selecting a larger or smaller size than the 3.0 cm dividing
point used in the extant staging system,25,26,36,37 we opted to
stay with 3.0 cm for two reasons. First, patients with lesions
greater than 3.0 cm have a survival that mirrors that of
patients with stage IIA disease (T1N1M0),29 and, second,
virtually all lung cancer experts agree that stage IIA patients
are reasonable candidates for adjuvant chemotherapy.1–3
The number of mediastinal lymph nodes assessed and
the “adequacy” of lymph node dissection during thoracotomy
are also important staging parameters to consider. What
constitutes an “adequate” lymph node dissection or sampling
is not well defined,38 although a recently completed American
College of Surgeons Oncology Group trial may help clarify
these issues. We believe a reasonable minimum standard
entails a complete mediastinal lymph node dissection or a
systematic mediastinal lymph node sampling of at least one
node from levels 4, 7, and 10R for right-sided lesions and
levels 5, 6, 7, and 10L (if present) for left-sided lesions.39
How many nodes one needs to examine also is not well
established. However, survival after resection of NSCLC is
associated with the total number of lymph nodes evalu-
ated,39–41 in keeping with findings for other solid tumors.42,43
FIGURE 2. Survival curves for stage IB (T2N0M0) and IIA
(T1N1M0) non-small cell lung cancer. Data obtained from
surgical series in the United States (MDA, M.D. Anderson
Cancer Center [24 patients] and The Netherlands (D, Dutch
group [27 patients]).
FIGURE 3. Algorithm for selecting stage I non-small cell
lung cancer (NSCLC) patients for postoperative adjuvant
chemotherapy. ECOG PS, Eastern Cooperative Oncology
Group performance status; CCI, Charlson Comorbidity In-
dex; CT, chemotherapy; VPI, visceral pleural invasion; LVI,
lymphovascular invasion; LND, lymph node dissection; LNS,
lymph node sampling.
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Presumably, this is due to more accurate staging, although
some clinicians have attributed the better outcome to a
therapeutic effect of the lymph node dissection (a highly
controversial issue).44,45 Some investigators report improved
staging accuracy and survival when more than 15 nodes are
examined,41,46 whereas others report no incremental survival
benefit after examination of nine nodes.39 Of some concern is
the ability of the pathologist to distinguish between lymph
node fragments and intact lymph nodes. Multiple fragments
may arise from one node and should not be counted as
multiple nodes. The pathologist must consistently sample
multiple sections of the nodal tissue. A simple bisection is
usually inadequate. In our algorithm, we purposely left the
total number of nodes vague, although some might justifiably
argue for a number of 9 or more based on the results of a
CALGB study.39
Additional tumor-related parameters such as lympho-
vascular invasion47–49 or cavitation50 are associated with a
worse prognosis in early-stage disease. The prognostic im-
pact of histology is less clear, although adenocarcinomas are
more prone to extrathoracic metastases.29 Thus, some oncolo-
gists may be inclined to use this tumor factor in their decision
algorithm.
Key host-related factors contained within the algorithm
are performance status and the presence of comorbidities,
which serve as independent prognostic factors in stage I
disease.51 As performance status worsens, a patient’s ability
to tolerate treatment diminishes and toxicities caused by
therapy tend to be more frequent and severe.52 Comorbidities
are common in patients with NSCLC and affect prognosis
adversely.52–54 Comorbidities associated with a particularly
poor outcome include significant cardiovascular disease, a
connective tissue disorder, and moderate to severe liver
disease.52–54 Calculating the Charlson index can be a useful
method to assess comorbidities (Table 3).55 A high Charlson
score correlates with poor survival.51,52 A less well defined
host-related factor is postoperative recovery time. Most mod-
ern adjuvant trials tended to initiate chemotherapy within 6 to
8 weeks of thoracotomy. Although empirical, we selected the
8-week interval to begin treatment. Initiating treatment after
an 8-week delay has unknown benefit.
TREATMENT RECOMMENDATIONS
As shown in Figure 3, a patient must first be a reason-
able candidate for chemotherapy to be considered for adju-
vant treatment. We would not recommend adjuvant therapy
to patients with a poor performance status (i.e., Eastern
Cooperative Oncology Group performance status2), excess
comorbidities as assessed by the Charlson score (i.e., score
3), or in the event of a prolonged postoperative recovery
time (i.e., 8 weeks). We would recommend adjuvant che-
motherapy for a stage I NSCLC patient with a primary lesion
larger than 3 cm or VPI, a good performance status (i.e.,
0–1), and no or few comorbidities. We would also consider
adjuvant chemotherapy for a patient with a tumor smaller
than 3 cm (i.e., stage IA) if the lymph node dissection or
sampling proved inadequate and the patient was otherwise in
good condition. Of course if such a recommendation was
proffered, the patient would need to be fully informed as to
the possibility of harm due to adjuvant therapy as suggested
(but not proved) by the Lung Adjuvant Cisplatin Evaluation
meta-analysis.17
Regarding chemotherapy options, the extant data most
strongly support the use of cisplatin plus vinorelbine, al-
though other combinations can be justified.5,6,13,17 Some on-
cologists may prefer carboplatin in the adjuvant setting, but
the negative result of the CALGB trial dampens our enthu-
siasm for this agent. In addition, at least two recent random-
ized trials in advanced NSCLC suggest carboplatin is inferior
to cisplatin in terms of overall survival.56,57 If true, the minor
survival differences observed in advanced disease could be
magnified in the adjuvant setting.58 Moreover, given the
improved tolerance of cisplatin administration with modern
supportive care, cisplatin use can be encouraged in patients
with good performance status. Nevertheless, circumstances
may arise where carboplatin would be used preferentially
over cisplatin. For example, a patient with poor renal function
(i.e., glomerular filtration rate 60 ml/min) or a preexisting
neuropathy or hearing loss might be a candidate for adjuvant
treatment with carboplatin-based therapy.
SUMMARY
Over the past decade it has become increasingly clear
that chemotherapy has had a substantial impact on the sur-
vival of individuals with early-stage NSCLC.16–18 However,
as was the case early on in the evolution of adjuvant therapy
in breast cancer, some clinicians believe only patients with
high-risk features derive benefit from adjuvant therapy. Ad-
juvant therapy improves survival in all subgroups of women
with invasive breast cancer, although the absolute benefit
varies depending on tumor stage and other prognostic fea-
tures.59 We anticipate that similar findings will emerge with
adjuvant therapy in early-stage NSCLC. Like breast cancer,
the magnitude of benefit simply may be more difficult to
discern in certain subgroups of lung cancer patients. Fortu-
nately, there are several exciting technologies on the horizon
that may soon permit oncologists to prospectively assign
NSCLC patients to “good” or “bad” survival categories and
help guide treatment decisions.60–62 However, until these
newer technologies are proved to be reliable predictors of
TABLE 3. Charlson Comorbidity Index Scoring55
Score Condition
1 Coronary artery disease, congestive heart failure, chronic
pulmonary disease, peptic ulcer disease, peripheral vascular
disease, mild liver disease, cerebrovascular disease, connective
tissue disease, diabetes, dementia
2 Hemiplegia, moderate to severe renal disease
Diabetes with end-organ damage, any previous tumor
(within 5 yr of diagnosis), leukemia, lymphoma
3 Moderate to severe liver disease
6 Metastatic solid tumor, acquired immunodeficiency syndrome
(not only human immunodeficiency virus positive)
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treatment response and survival, a common-sense clinical
approach to treatment in stage I NSCLC is needed. The
proposed decision algorithm should help clinicians select
patients for adjuvant therapy. Admittedly, we have formu-
lated an empirical approach based on clinical judgment and
available evidence in an “age of molecular medicine.” Nearly
a century ago, Sir William Osler observed “Variability is the
law of life, and as no two faces are the same, so no two bodies
are alike, and no two individuals react alike and behave alike
under the abnormal conditions which we know as disease.”
So it is with stage I NSCLC. Until additional evidence is
produced, refined clinical judgment is needed in managing
patients with stage I NSCLC.63
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ERRATUM
Wang SJ, Fuller CD, Thomas CR Jr. Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer. J Thorac Oncol
2006;2(3):180–190.
In the original research article entitled “Ethnic Disparities in Conditional Survival of Patients with Non-small Cell Lung Cancer”, [1] which appeared in
the March 2007 issue of the Journal of Thoracic Oncology, the Figure 1 caption stated that the slope of the survival curve represented the instantaneous
hazard rate. In actuality, the slope of the survival curve, St, represents the negative of the probability density function, ft, the probability of an event
occurring at time t [2], which can be written as:
dSt
dt   ft
The hazard rate, t, the instantaneous rate of occurrence of an event at time t, is actually defined as the probability density at time t divided by the survival
at time t:
t
ft
St
The subsequent conditional survival calculations in the article remain unchanged.
The authors are grateful to John Crowley, PhD, Director of the Southwest Oncology Group Statistical Center, for bringing this correction to our attention.
1. Wang SJ, Fuller CD, Thomas CR. Ethnic disparities in conditional survival of patients with non-small cell lung cancer. J Thorac Oncol 2007;
2(3):180–190.
2. Tableman M, Kim JS. Survival analysis using S: Analysis of time to event data. 1st ed. Chapman & Hall/CRC; 2003.
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